Literature DB >> 15081525

Regulation of mast cell activation by complement-derived peptides.

Anna Erdei1, Márton Andrásfalvy, Hajna Péterfy, Gábor Tóth, Israel Pecht.   

Abstract

It is known for more than 25 years that the complement-derived anaphylatoxic peptides, C3a, C4a and C5a are potent activators of basophils and certain types of mast cells. Although tissue distribution of receptors for C3a and C5a well exceeds myeloid cells, apparently they are not expressed on mucosal type mast cells, consequently these cells are not activated by C3a and C5a. Our results do however demonstrate that C3a and peptides related to this complement activation product are able to inhibit FcRI-clustering induced activation of mucosal type mast cells-such as RBL-2H3 cells and bone-marrow derived mast cells. Based on the current results we propose the presence of separate "activator" and "inhibitor" sequence motifs in C3a which are in balance under physiologic conditions.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15081525     DOI: 10.1016/j.imlet.2003.11.019

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  17 in total

1.  G protein coupled receptor specificity for C3a and compound 48/80-induced degranulation in human mast cells: roles of Mas-related genes MrgX1 and MrgX2.

Authors:  Sakeen W Kashem; Hariharan Subramanian; Sarah J Collington; Paola Magotti; John D Lambris; Hydar Ali
Journal:  Eur J Pharmacol       Date:  2011-07-03       Impact factor: 4.432

Review 2.  Roles of Mas-related G protein-coupled receptor X2 on mast cell-mediated host defense, pseudoallergic drug reactions, and chronic inflammatory diseases.

Authors:  Hariharan Subramanian; Kshitij Gupta; Hydar Ali
Journal:  J Allergy Clin Immunol       Date:  2016-07-20       Impact factor: 10.793

3.  Transcriptional control of complement activation in an exercise model of chronic fatigue syndrome.

Authors:  Bristol Sorensen; James F Jones; Suzanne D Vernon; Mangalathu S Rajeevan
Journal:  Mol Med       Date:  2008-11-10       Impact factor: 6.354

4.  Complement activation in the Parkinson's disease substantia nigra: an immunocytochemical study.

Authors:  David A Loeffler; Dianne M Camp; Stephanie B Conant
Journal:  J Neuroinflammation       Date:  2006-10-19       Impact factor: 8.322

Review 5.  Anaphylatoxin C3a receptors in asthma.

Authors:  Hydar Ali; Reynold A Panettieri
Journal:  Respir Res       Date:  2005-02-21

6.  Therapeutic effects of sesame oil on monosodium urate crystal-induced acute inflammatory response in rats.

Authors:  Dur-Zong Hsu; Si-Jin Chen; Pei-Yi Chu; Ming-Yie Liu
Journal:  Springerplus       Date:  2013-12-07

Review 7.  Mast cell mediators: their differential release and the secretory pathways involved.

Authors:  Tae Chul Moon; A Dean Befus; Marianna Kulka
Journal:  Front Immunol       Date:  2014-11-14       Impact factor: 7.561

Review 8.  Amniotic fluid embolism pathophysiology suggests the new diagnostic armamentarium: β-tryptase and complement fractions C3-C4 are the indispensable working tools.

Authors:  Francesco Paolo Busardò; Paola Frati; Simona Zaami; Vittorio Fineschi
Journal:  Int J Mol Sci       Date:  2015-03-23       Impact factor: 5.923

9.  Mast cells regulate myofilament calcium sensitization and heart function after myocardial infarction.

Authors:  Anta Ngkelo; Adèle Richart; Jonathan A Kirk; Philippe Bonnin; Jose Vilar; Mathilde Lemitre; Pauline Marck; Maxime Branchereau; Sylvain Le Gall; Nisa Renault; Coralie Guerin; Mark J Ranek; Anaïs Kervadec; Luca Danelli; Gregory Gautier; Ulrich Blank; Pierre Launay; Eric Camerer; Patrick Bruneval; Philippe Menasche; Christophe Heymes; Elodie Luche; Louis Casteilla; Béatrice Cousin; Hans-Reimer Rodewald; David A Kass; Jean-Sébastien Silvestre
Journal:  J Exp Med       Date:  2016-06-27       Impact factor: 14.307

10.  Inflammation and tumor progression: signaling pathways and targeted intervention.

Authors:  Huakan Zhao; Lei Wu; Guifang Yan; Yu Chen; Mingyue Zhou; Yongzhong Wu; Yongsheng Li
Journal:  Signal Transduct Target Ther       Date:  2021-07-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.